细胞黏附分子与慢性心力衰竭不良结局:DAPA-HF随机临床试验的发现
该研究基于DAPA-HF随机临床试验的生物标志物亚组,测量3051例射血分数降低的心力衰竭(HFrEF)患者基线和12个月时的VCAM-1与ICAM-1水平。
要点
- HFrEF患者基线VCAM-1最高三分位与主要复合终点风险独立相关。
- ICAM-1水平与任何结局风险升高无关。
- 达格列净降低主要终点的获益在各VCAM-1三分位间一致。
核心结论
- 在HFrEF患者中,较高VCAM-1水平与更差结局相关,即使校正常规预后变量后仍显著。
- ICAM-1水平与任何结局风险升高无关。
- 达格列净与安慰剂相比降低主要终点风险的获益在各VCAM-1三分位间一致。
- 达格列净治疗52周未显著改变VCAM-1水平。
研究设计与样本
- DAPA-HF随机临床试验的生物标志物亚组分析,纳入3051例HFrEF患者(平均年龄67.2岁,男性78.2%)。
- 在基线和12个月测量VCAM-1与ICAM-1水平,平均随访17.6个月。
- 主要终点为心力衰竭恶化事件或心血管死亡的复合终点,采用Cox比例风险回归模型校正已知预后变量。
主要发现
- 基线VCAM-1中位数(IQR)为997(816.7-1218.8)ng/mL。
- ICAM-1水平与任何结局风险升高无关。
临床怎么用
- VCAM-1可作为HFrEF患者炎症/免疫通路相关预后评估的潜在生物标志物。
- 达格列净的临床获益不受基线VCAM-1水平影响,各三分位患者均可考虑使用。
局限性
- 本研究为DAPA-HF试验的生物标志物亚组分析,结果需在其他HFrEF队列中验证。
- VCAM-1与ICAM-1仅在基线和12个月测量,未评估动态变化与结局的关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Vascular cell adhesion molecule 1 (VCAM-1) and intracellular cell adhesion molecule 1 (ICAM-1) are responsible for immune cell-cell interactions. Systemic levels of VCAM-1 are associated with incident heart failure (HF). OBJECTIVES: To determine if VCAM-1 and ICAM-1 levels are associated with progression of established HF. DESIGN, SETTING, AND PARTICIPANTS: Participants enrolled in the biomarker substudy of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) randomized clinical trial had VCAM-1 and ICAM-1 levels measured at baseline and 12 months. The DAPA-HF trial was conducted at 410 sites in 20 countries. Patients with HF and reduced ejection fraction (HFrEF) in New York Heart Association (NYHA) class II to IV with elevated natriuretic peptides were enrolled between February 15, 2017, and August 17, 2018, with final follow-up on June 6, 2019. Data were analyzed from January 2023 to January 2025. INTERVENTIONS: Dapagliflozin, 10 mg, once daily vs placebo. MAIN OUTCOMES AND MEASURES: The primary outcome was the composite of a worsening HF event or cardiovascular death. The associations between VCAM-1 and ICAM-1 levels at baseline and the primary outcome, its components, and all-cause death were analyzed using Cox proportional hazards regression models adjusted for known prognostic variables including estimated glomerular filtration rate (eGFR), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high-sensitivity troponin T (hs-TnT), as well as high-sensitivity C-reactive protein. RESULTS: A total of 3051 participants (mean [SD] age, 67.2 [10.5] years; 2386 male [78.2%]) were included in this study. Mean (SD) follow-up time was 17.6 (5.2) months. The median (IQR) baseline VCAM-1 level was 997 (816.7-1218.8) ng/mL. Compared with patients with lower concentrations of VCAM-1, those with higher concentrations of VCAM-1 were older (mean [SD] age T3 vs T1, 69.7 [9.7] years vs 64.1 [10.7] years; P < .001), in worse NYHA class (T3 vs T1, NYHA class III/IV 35.6% [362 of 1017] vs 26.5% [269 of 1017]; P < .001), and had higher NT-proBNP (median [IQR] T3 vs T1, 2018 [1126-3753] pg/mL vs 1118 [693-1830] pg/mL) and hs-TnT (median [IQR] T3 vs T1, 24.7 [17.1-37.5] ng/L vs 16.6 [11.6-24.9] ng/L) concentrations, and lower eGFR (mean [SD] T3 vs T1, 58.4 [17.6] mL/min/1.73 m2 vs 71.7 [18.0] mL/min/1.73 m2). Patients in tertile 3 of VCAM-1, compared with tertile 1, had the highest risk of each outcome (eg, adjusted hazard ratio [HR] for primary outcome 1.40; 95% CI, 1.11-1.77; P = .004). ICAM-1 level was not associated with an elevated risk of any outcome. The benefit of dapagliflozin vs placebo in reducing the risk of the primary outcome was consistent across VCAM-1 tertiles: HR, 0.76 (95% CI, 0.54-1.06), 0.82 (95% CI, 0.59-1.12), and 0.77 (95% CI, 0.61-0.98) for tertiles 1, 2 and 3, respectively (P for interaction = .93). There was no significant change in VCAM-1 level with dapagliflozin at 52 weeks. CONCLUSIONS AND RELEVANCE: Results of this substudy of the DAPA-HF randomized clinical trial demonstrate that higher VCAM-1 levels, possibly reflecting a distinct inflammatory/immune pathophysiological pathway in HFrEF, were associated with worse outcomes, even after adjustment for conventional prognostic variables. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03036124.
引用
- McDowell, Welsh, Docherty, et al. Cellular Adhesion Molecules and Adverse Outcomes in Chronic Heart Failure: Findings From the DAPA-HF Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 40465275. doi:10.1001/jamacardio.2025.1592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。